Artelo Biosciences, Inc. (ARTL) has a negative trailing P/E of -1.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 0.4 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -82.19%, forward earnings yield 238.10%. PEG 0.01 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 30/100 with 1/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -444.0 | -4.63 | -955.27 | 0.00 | - |
| 2017 | -64.1 | -0.11 | 27.65 | 0.00 | - |
| 2018 | -7.5 | -0.01 | -130.22 | 0.00 | - |
| 2019 | -5.8 | 0.13 | 2.31 | 0.00 | - |
| 2020 | -2.3 | -0.09 | 2.75 | 0.00 | - |
| 2021 | -6.9 | 0.10 | 4.24 | 0.00 | - |
| 2022 | -2.4 | 0.06 | 1.27 | 0.00 | - |
| 2023 | -8.0 | 0.80 | 6.35 | 0.00 | - |
| 2024 | -6.3 | 2.18 | 21.52 | 0.00 | - |
| 2025 | -0.2 | 0.00 | -2.26 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.47 | $0.00 | $-29.69K | - |
| 2017 | $-3.23 | $0.00 | $-234.89K | - |
| 2018 | $-27.52 | $0.00 | $-2.34M | - |
| 2019 | $-15.00 | $0.00 | $-2.17M | - |
| 2020 | $-18.83 | $0.00 | $-4.65M | - |
| 2021 | $-5.97 | $0.00 | $-7.44M | - |
| 2022 | $-3.49 | $0.00 | $-10.08M | - |
| 2023 | $-1.05 | $0.00 | $-9.29M | - |
| 2024 | $-1.02 | $0.00 | $-9.83M | - |
| 2025 | $-5.47 | $0.00 | $-12.88M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-9.84 | $-9.84 – $-9.84 | $0.00 | $0.00 – $0.00 | 1 |
| 2027 | $-5.28 | $-5.28 – $-5.28 | $49.29M | $49.29M – $49.29M | 1 |
| 2028 | $12.60 | $12.60 – $12.60 | $99.56M | $99.56M – $99.56M | 1 |
| 2029 | $30.15 | $30.15 – $30.15 | $184.73M | $184.73M – $184.73M | 1 |
| 2030 | $40.62 | $40.62 – $40.62 | $245.3M | $245.3M – $245.3M | 1 |
